1. Home
  2. DOMH vs BCDA Comparison

DOMH vs BCDA Comparison

Compare DOMH & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • BCDA
  • Stock Information
  • Founded
  • DOMH 1967
  • BCDA N/A
  • Country
  • DOMH United States
  • BCDA United States
  • Employees
  • DOMH N/A
  • BCDA N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • BCDA Health Care
  • Exchange
  • DOMH Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • DOMH 8.8M
  • BCDA 7.9M
  • IPO Year
  • DOMH N/A
  • BCDA N/A
  • Fundamental
  • Price
  • DOMH $3.02
  • BCDA $2.54
  • Analyst Decision
  • DOMH
  • BCDA Strong Buy
  • Analyst Count
  • DOMH 0
  • BCDA 1
  • Target Price
  • DOMH N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • DOMH 427.5K
  • BCDA 54.1K
  • Earning Date
  • DOMH 03-31-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • DOMH N/A
  • BCDA N/A
  • EPS Growth
  • DOMH N/A
  • BCDA N/A
  • EPS
  • DOMH N/A
  • BCDA N/A
  • Revenue
  • DOMH $12,589,000.00
  • BCDA $71,000.00
  • Revenue This Year
  • DOMH N/A
  • BCDA N/A
  • Revenue Next Year
  • DOMH N/A
  • BCDA N/A
  • P/E Ratio
  • DOMH N/A
  • BCDA N/A
  • Revenue Growth
  • DOMH 1117.50
  • BCDA N/A
  • 52 Week Low
  • DOMH $0.83
  • BCDA $0.32
  • 52 Week High
  • DOMH $4.35
  • BCDA $5.70
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 65.22
  • BCDA 56.72
  • Support Level
  • DOMH $2.86
  • BCDA $2.12
  • Resistance Level
  • DOMH $4.35
  • BCDA $2.73
  • Average True Range (ATR)
  • DOMH 0.52
  • BCDA 0.22
  • MACD
  • DOMH 0.14
  • BCDA 0.03
  • Stochastic Oscillator
  • DOMH 53.19
  • BCDA 58.21

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: